Trial reportBritish journal of cancer2006
Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.
Trial report in British journal of cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Using proton pump inhibitors increases the risk of hepato-biliary-pancreatic cancer. A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Pooled it
- CCK-1R-selective and non-selective cholecystokinin antagonists, lorglumide, and proglumide increased toxicity of carboplatin to granulocyte-macrophage progenitor cells (CFU-GM) of bone marrow of rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation.Cancer communications (London, England) · 2025Review
- Structures of the human cholecystokinin receptors bound to agonists and antagonists.Nature chemical biology · 2021Article
- Article
- Fluorinated phenylalanines: synthesis and pharmaceutical applications.Beilstein journal of organic chemistry · 2020Review
- Gastrin stimulates pancreatic cancer cell directional migration by activating the Gα12/13-RhoA-ROCK signaling pathway.Experimental & molecular medicine · 2018Article
- First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis.Cancer management and research · 2018Article
- Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study.PloS one · 2018Article
- Gastrin and Gastric Cancer.Cellular and molecular gastroenterology and hepatology · 2017Review
- Proton pump inhibitors on pancreatic cancer risk and survival.Cancer epidemiology · 2017Article
- Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice.Pancreas · 2014Article
- Risk factors and therapeutic targets in pancreatic cancer.Frontiers in oncology · 2013Review
- Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes.Molecular cancer research : MCR · 2012Article
- Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis.American journal of physiology. Gastrointestinal and liver physiology · 2012Article
- Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study.British journal of cancer · 2012Article
- Current knowledge on pancreatic cancer.Frontiers in oncology · 2012Article
- Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer.Cancer science · 2010Article
- Systemic therapy for metastatic pancreatic adenocarcinoma.Therapeutic advances in medical oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrin has been shown to be a growth stimulant in pancreatic cancer cells. Gastrazole is a potent and selective gastrin receptor antagonist. Two randomised blinded trials were conducted to assess the effect of gastrazole in advanced pancreatic cancer. Patients with biopsy-proven, inoperable pancreatic carcinoma were recruited. Trial A compared protracted venous infusion (PVI) gastrazole with PVI placebo, whereas trial B compared PVI gastrazole with PVI fluorouracil (5-FU). Eighteen patients were randomised in trial A. Gastrazole produced significantly better survival compared to placebo (median 7.9 months vs 4.5 months; 1-year survival: 33 vs 11%, respectively; log rank P=0.02). No difference in toxicity was seen between gastrazole and placebo, except central venous catheter and pump complications. Ninety-eight patients were randomised in trial B. No significant survival difference was detected between gastrazole and 5-FU (median: 3.6 vs 4.2 months; 1-year survival: 13.2 vs 26.2%, respectively; log rank P=0.42). Toxicity of gastrazole was mild with significantly less diarrhoea (P=0.03), stomatitis (P<0.001) and hand- foot syndrome (P<0.001) compared to 5-FU. Quality of life (QoL) assessment showed similar QoL between gastrazole and 5-FU at baseline and no significant differences occurred with treatment either between arms or within arms. Compared to placebo, patients with advanced pancreatic cancer treated with gastrazole appeared to live longer, albeit in a very small trial and will require confirmation with large-scale randomised data. However, it did not produce survival advantage over PVI 5-FU. Lack of toxicity for gastrazole may allow its combination with cytotoxic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.